AlphaYou
Overview
Smart money at a glance
Filings to Oct 1, 2026Net selling: insiders sold $7.2M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- -$7.2M netNet selling
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 3 added, 1 cutMore adding
- Federal contractsUSAspending.gov, last 12 months
- No awardsNone on record
Key stats
Fundamentals Sep 30- Open
- $30.56
- 52-wk high
- $33.66
- High
- $30.60
- 52-wk low
- $20.03
- Low
- $29.61
- Prev close
- $30.92
- Mkt cap
- $13.43B
- Volume
- 5.07M
- Fwd P/E
- 9.5x
- Beta
- 1.60
- Div yield
- 2.79%
- P/S
- 1.9x
- P/B
- 1.4x
- Profit margin
- -0.9%
- Op margin
- +20.0%
- ROE
- -0.6%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about IVZ filings
Are insiders buying or selling Invesco Plc (IVZ) stock?
Net selling: insiders sold $7.2M and bought $0 of IVZ stock on the open market in the 90 days to Oct 1, 2026, according to SEC Form 4 filings. The largest was Lo, Andrew Tak Shing (Senior Managing Director), who sold $4.6M. The latest filing was on Sep 14, 2026.
Which members of Congress have traded IVZ recently?
None. No member of Congress disclosed a IVZ trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this IVZ smart-money data?
This summary uses filings available on Oct 1, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Buys/Adds (2)
- QR
Qube Research
$78.4M
added
- CI
Citadel
$41.7M
added
Sells/Trims (1)
- P7
Point72
$38.9M
sold
What insiders are doing
What Congress is doing
Sells (1)
How top traders are positioned
No tracked top-trader positions in IVZ right now.
Live Hyperliquid positioning - not every stock is covered
Earnings
Earnings came in 6.0% above what analysts expected.
Earnings per share
$0.67 expected
Reports Oct 27, 2026, in 26 days
Estimates as of Sep 30, 2026
EPS expected
$0.70 to $0.76
Revenue expected
4 analysts
Last 30 days
Analysts cutting estimates
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $1.64B | $1.69B | $1.74B | $1.83B |
| Cost of what it sold | $1.08B | $559.1M | $601.4M | $8.1M |
| Gross profit | $560.5M | $1.13B | $1.14B | $1.82B |
| What it spent | ||||
| Sales and admin | $151.3M | $148.7M | $147.1M | $133.5M |
| Other operating costs | $138.3M | $2.44B | $662.8M | $1.32B |
| Total operating expenses | $289.6M | $2.59B | $809.9M | $1.45B |
| What was left | ||||
| Operating profit | $270.9M | -$1.46B | $333.2M | $364.2M |
| Interest on debt | $25.7M | $23.0M | $24.3M | $23.6M |
| Profit before tax | $346.7M | -$1.35B | $300.2M | $455.4M |
| Tax | -$9.7M | -$349.5M | $81.1M | $116.5M |
| Net profit | $345.7M | -$1.06B | $268.6M | $382.3M |
| EBITDA | $410.7M | $231.4M | $357.7M | $487.1M |
Technicals
Price structure
This stock is under pressure.
Trend
Under pressure
25 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage is bullish
Did International ETF Launch Just Shift Invesco (IVZ) Stock Narrative?
NeutralSep 26ETFs Investing in Jiade Limited Class A Stocks
NeutralSep 26Invesco (NYSE:IVZ) Stock Rating Cut to "Hold" at Wall Street Zen
Leans bearishSep 26Invesco Income Allocation Fund Q2 2026 Commentary (Mutual Fund:ALAAX)
Leans bullishSep 25Principal faces fresh ERISA challenge over LifeTime Hybrid funds — this time in its own 401(k) plan
Leans bullishSep 253 Top-Ranked Invesco Mutual Funds Poised for Massive Returns
BullishSep 25Morgan Stanley Adjusts Price Target on T. Rowe Price to $110 From $116, Keeps Equalweight Rating
NeutralSep 25Morgan Stanley Adjusts Price Target on Invesco to $31 From $30, Keeps Equalweight Rating
Leans bullishSep 25